发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
P-022 Discovery of Shared, MHC-Promiscuous Antigens in Multiple Myeloma Patients P-022 发现多发性骨髓瘤患者共有的 MHC 杂合抗原
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01925-6
{"title":"P-022 Discovery of Shared, MHC-Promiscuous Antigens in Multiple Myeloma Patients","authors":"","doi":"10.1016/S2152-2650(24)01925-6","DOIUrl":"10.1016/S2152-2650(24)01925-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-31 TRIM28 Functions as a Key Protein Homeostasis Regulator and Mediates Proteasome Inhibitor Resistance in MM OA-31 TRIM28作为关键蛋白稳态调节器发挥功能并介导 MM 中蛋白酶体抑制剂的抗性
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01872-X
{"title":"OA-31 TRIM28 Functions as a Key Protein Homeostasis Regulator and Mediates Proteasome Inhibitor Resistance in MM","authors":"","doi":"10.1016/S2152-2650(24)01872-X","DOIUrl":"10.1016/S2152-2650(24)01872-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) 用于复发性/难治性多发性骨髓瘤 (RRMM) 患者 (pts)：TRIMM-2 1b 期研究结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01842-1
{"title":"OA-01 Talquetamab (tal) + Daratumumab (dara) + Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study","authors":"","doi":"10.1016/S2152-2650(24)01842-1","DOIUrl":"10.1016/S2152-2650(24)01842-1","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-02 Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma OA-02 对脐带血 CAR NK 细胞进行多重 CRISPR/Cas9 基因组编辑，提高其持久性和抗多发性骨髓瘤的潜力
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01843-3
{"title":"OA-02 Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01843-3","DOIUrl":"10.1016/S2152-2650(24)01843-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-07 A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma OA-07 复发性或难治性多发性骨髓瘤的标准疗法 Idecabtagene Vicleucel 与 Ciltacabtagene Autoleucel CAR T 细胞疗法的比较
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01848-2
{"title":"OA-07 A Comparison of Standard of Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR T-cell Therapy in Relapsed or Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01848-2","DOIUrl":"10.1016/S2152-2650(24)01848-2","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-027 Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma P-027 在复发性和难治性多发性骨髓瘤患者中应用标准疗法 Talquetamab 的真实体验
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01930-X
{"title":"P-027 Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01930-X","DOIUrl":"10.1016/S2152-2650(24)01930-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-016 Comparative Efficacy of CARVYKTI in CARTITUDE-4 versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma P-016 CARVYKTI在CARTITUDE-4中的疗效与达拉单抗临床试验中治疗来那度胺难治性多发性骨髓瘤患者的替代疗法比较
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01919-0
{"title":"P-016 Comparative Efficacy of CARVYKTI in CARTITUDE-4 versus Alternative Treatments from Daratumumab Clinical Trials for the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01919-0","DOIUrl":"10.1016/S2152-2650(24)01919-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-16 Long-Term Evaluation of Minimal Residual Disease Dynamics in Multiple Myeloma Patients Achieving Complete Response After First Line Treatment OA-16 对一线治疗后获得完全应答的多发性骨髓瘤患者最小残留病动态的长期评估
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01857-3
{"title":"OA-16 Long-Term Evaluation of Minimal Residual Disease Dynamics in Multiple Myeloma Patients Achieving Complete Response After First Line Treatment","authors":"","doi":"10.1016/S2152-2650(24)01857-3","DOIUrl":"10.1016/S2152-2650(24)01857-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-60 The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma OA-60 含有新型天麻素有效载荷的抗 BCMA 抗体-药物共轭物 HDP-101 在复发性多发性骨髓瘤中的首次人体试验结果令人鼓舞
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01901-3
{"title":"OA-60 The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01901-3","DOIUrl":"10.1016/S2152-2650(24)01901-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-28 MM Progression and Evolution of Refractory Disease Explained by Integrative Multiomics in Moffitt Cancer Center's Patient Cohort OA-28 莫菲特癌症中心患者队列中的整合多组学解释 MM 进展和难治性疾病的演变
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01869-X
{"title":"OA-28 MM Progression and Evolution of Refractory Disease Explained by Integrative Multiomics in Moffitt Cancer Center's Patient Cohort","authors":"","doi":"10.1016/S2152-2650(24)01869-X","DOIUrl":"10.1016/S2152-2650(24)01869-X","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信